nintedanib makes a dramatic difference to idiopathic pulmonary fibrosis -lrb- ipf -rrb- .
the condition affects mainly men and former smokers , causes inflammation and scarring of the lung tissue .
sufferers have an average life expectancy of between three and five years , with 5,000 deaths and 5,000 new cases every year .
the drug is now likely to be licensed worldwide within the next year , and avail-able to patients in the near future .